https://allsci.com/news/clinical-trials/efzimfotase-alfa-astrazenecas-misses-phase-iii/ AllScien 2026-10-13T13:25:16.559050Z AstraZeneca details Phase III HICKORY endpoint miss for efzimfotase alfa in hypophosphatasia https://allsci.com/news/grants/ultra-rare-sarcomas-sloan-kettering-receives-15m/ AllScien 2026-10-13T13:08:32.522353Z FDA awards Sloan-Kettering USD 1.5m for rare sarcoma drug target discovery https://allsci.com/news/clinical-trials/axatilimab-pulmonary-fibrosis-maxpire-failure/ AllScien 2026-10-13T12:58:50.320311Z MAXPIRe failure ends Syndax's axatilimab program in idiopathic pulmonary fibrosis https://allsci.com/news/licensing-and-partnerships/micurx-adc-license-plans-to-out-license/ AllScien 2026-10-13T11:13:39.470990Z MicuRx plans ADC licensing deal with ClearideBio worth up to USD 974 million in disclosed payments https://allsci.com/news/clinical-trials/livmarli-cholestatic-pruritus-cuts-in-phase-iii/ AllScien 2026-10-13T11:04:04.896291Z Mirum's Livmarli meets Phase III endpoint in ultra-rare cholestatic liver diseases https://allsci.com/news/clinical-trials/celiac-disease-trial-anb033-meets-key-histologic/ AllScien 2026-10-13T10:12:11.663872Z First Tracks' ANB033 meets histologic endpoints in Phase Ib celiac disease trial https://allsci.com/news/clinical-trials/remigromig-dme-meets-non-inferiority-primary/ AllScien 2026-10-13T09:25:24.814346Z Merck's remigromig meets Phase III DME endpoint, but retinopathy safety signal emerges https://allsci.com/news/clinical-trials/ryz101-action-1-trial-meets-primary-pfs-endpoint/ AllScien 2026-10-13T08:42:34.733503Z BMS' RYZ101 meets Phase III endpoint in landmark alpha-radiopharmaceutical trial https://allsci.com/news/clinical-trials/admilparant-ipf-phase-iii-aloft-ipf-trial-of/ AllScien 2026-10-12T20:13:32.064551Z BMS' admilparant meets Phase III IPF endpoint at lower dose, misses at higher dose https://allsci.com/news/clinical-trials/obuprazine-schizophrenia-hits-primary-endpoint/ AllScien 2026-10-12T18:57:48.542156Z Tortugas boosted by positive China Phase II data for obuprazine in schizophrenia https://allsci.com/news/biotech/aumolertinib-eu-application-hansoh-resubmits/ AllScien 2026-10-12T17:31:25.776453Z Hansoh resubmits aumolertinib EU marketing application after data protection revocation https://allsci.com/news/clinical-trials/icotrokinra-psoriasis-sustains-pasi-90-response-1/ AllScien 2026-10-12T16:18:54.192529Z J&J's oral Icotyde sustains psoriasis clearance through two years in Phase III trial https://allsci.com/news/licensing-and-partnerships/dituo-biopharmaceutical-strikes-multi-target/ AllScien 2026-10-12T16:10:05.918001Z Roche partners with China's Defand Therapeutics on molecular glue degraders https://allsci.com/news/clinical-trials/nicotinamide-riboside-nopark-trial-finds-worsens/ AllScien 2026-10-12T16:05:41.898630Z NOPARK trial finds nicotinamide riboside worsens outcomes versus placebo in early Parkinson disease https://allsci.com/news/approvals/hovilpri-fda-approval-approves-for/ AllScien 2026-10-12T15:47:17.438886Z FDA approves Asahi Kasei's Hovilpri for treatment-refractory HSV infections https://allsci.com/news/clinical-trials/prifemilast-vs-apremilast-beats-on-both/ AllScien 2026-10-12T15:37:47.574713Z cAMPfield's China partner reports Phase III prifemilast superiority over apremilast in psoriasis https://allsci.com/news/approvals/weltruza-olanzapine-fda-approves-tevas-as-first/ AllScien 2026-10-12T15:11:16.819688Z FDA approves Teva's Weltruza as first once-monthly subcutaneous LAI for schizophrenia https://allsci.com/news/ipo-public-listing/city-therapeutics-ipo-seeks-usd-175m-in-to/ AllScien 2026-10-12T14:39:59.888674Z City Therapeutics seeks USD 175m in IPO to advance RNAi pipeline into 2028 https://allsci.com/news/biotech/chai-discovery-gsk-secures-collaboration-after/ AllScien 2026-10-12T14:34:33.571051Z Chai Discovery lands GSK deal after successful AI binder tests